Evotec Se · XETR:EVT
Evotec — Investor Presentation (April 2026)
38 slides from Evotec's investor presentation, April 2026
Slide 1: General company presentation
General company presentation Scientific Operational Excellence Excellence Evotec SE, Company presentation, April 2026
Slide 2: Disclaimer
Disclaimer This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the “Company”, “we,” “our” or “us”). This presentation is made pursuant to Sec
Slide 3: Pioneering Drug Discovery, Financials, Strategy & Outlook
1 Pioneering Drug Discovery 2 Financials 3 Strategy & Outlook PAGE 3
Slide 4: Unleashing innovation in drug discovery to develop life-changing medicines
Pioneering Drug Discovery Our purpose Unleashing innovation in drug discovery to develop life-changing medicines PAGE 4
Slide 5: Four levers of mid-term value creation
Four levers of mid-term value creation Above market growth rates at better-quality earnings Commitment to Operational Excellence Just – Evotec Biologics – better monetization of technology & assets Upside through returns on asset pipeline PAGE 5 1 Cumulative, non risk adjusted values
Slide 6: Lever 1: Above market growth rates at better-quality earnings
Lever 1: Above market growth rates at better-quality earnings Above market growth rates at better-quality earnings Technological leadership and innovation; steering portfolio towards high value segments Commitment to Operational Excellence Just – Evotec Biologics – better monetization of technology
Slide 7: Operating in highly attractive markets
Operating in highly attractive markets Outsourcing and paradigm shift as drivers for superior growth Global R&D spend Outsourcing share $ 260 bn • Global R&D spend with 3% growth 2023-2030 5-7% 40% Clinical 15% • Outsourcing trend continuing - drug discovery catching up CAGR (addressable CRO market
Slide 8: Innovative D&PD platforms drive high value partnerships
Innovative D&PD platforms drive high value partnerships Seamless AI enhanced DD platforms support expansion of co-owned asset pipeline Patient stratification In silico Target ID/ validation design Data Target ID / Hit Lead Pre-Clinical Clinical Sourcing Validation Identification Optimisation Develop
Slide 9: Versatile commercial model tailor-made to customers' needs
Versatile commercial model tailor-made to customers’ needs Targeted value proposition Our offerings Our value proposition Our commercial position 3 • Access to cutting edge technology, next-gen biology & AI Pioneering drug • Enhance drug discovery & development program Strategic partnerships & disco
Slide 10: Lever 2: Commitment to Operational Excellence
Lever 2: Commitment to Operational Excellence Above market growth rates at better-quality earnings Technological leadership and innovation; steering portfolio towards high value segments Commitment to Operational Excellence Accelerating cost-out plans & further productivity improvement Just – Evotec
Slide 11: Cost-out initiatives ahead of initial plan
Cost-out initiatives ahead of initial plan Cost reduction measures 2025 Impact ~ 600 FTE reduction in D&PD Measure Progress (Mar 24 – Jun 25); +200 FTE vs. Priority Reset Target • Remaining Priority Reset initiatives implemented • Disciplined spending & restricted hiring activities FY 2025 total cos
Slide 12: Lever 3: JEB - better monetization of technology & assets
Lever 3: JEB – better monetization of technology & assets Above market growth rates at better-quality earnings Technological leadership and innovation; steering portfolio towards high value segments Commitment to Operational Excellence Accelerating cost-out plans & further productivity improvement J
Slide 13: Just Evotec Biologics - better monetisation of technology & assets
Just Evotec Biologics – better monetisation of technology & assets Improving operational efficiency by focusing on technology leadership and core competencies Just – Evotec Biologics today Our vision for tomorrow Intellectual Expanding technology leadership Validated technology leadership property o
Slide 14: Fast track toward asset-lighter model
Fast track toward asset-lighter model Toulouse, France Evotec and Sandoz have signed the sale of Just – Evotec Biologics EU1, including the biologics manufacturing site (J.POD) located in Toulouse, France PAGE 14 1 Completion of transaction remains subject to consultation procedures with the French
Slide 15: Deal rationale
Deal rationale Transaction validates Evotec’s technology leadership and accelerates shift to asset-lighter model Strategic focus Transaction impact Technology • Huge endorsement by strong partner – Retaining high-value IP and core R&D competencies leadership • Leveraging technology advantage for sha
Slide 16: Attractive financial impact across multiple parameters
Attractive financial impact across multiple parameters Key deal parameters Key deal parameters, replacing existing commitments • Sale of Just – Evotec’s Biologics manufacturing site in Toulouse (J.POD)1 Scope • Technology license to operate J.POD, Toulouse based on Just – Evotec Biologics’ technolog
Slide 17: Assets in technical development
Supporting Sandoz in targeting US$ > 90 bn originator net sales JEB partnered biosimilars portfolio Originator net Loss of Exclusivity Targeted brand Indication sales (US$ bn) Darzalex® Europe: 2031 Assets in technical development Multiple Myeloma 17 daratumumab SC US: 2029 Enhertu® var. HER2-positi
Slide 18: Poised for long term growth
Poised for long term growth Next-generation CDMO model – Leveraging innovation, retaining platform control Leverage existing CDMO offerings Shaping new markets through innovation • IP licensing model for proprietary continuous manufacturing platform Full CDMO services Early and late- • Licensing of
Slide 19: Shaping the next generation CDMO model
Shaping the next generation CDMO model Accelerating growth – Enhancing margins – Improving capital return Continuation of existing commercial model ML enabled Molecule Complex Biologics Molecule Discovery Continuous mfg services Development Process Development Product Customer Traditional path enabl
Slide 20: Lever 4: Upside through returns on asset pipeline
Lever 4: Upside through returns on asset pipeline Above market growth rates at better-quality earnings Technological leadership and innovation; steering portfolio towards high value segments Commitment to Operational Excellence Accelerating cost-out plans & further productivity improvement Just – Ev
Slide 21: Asset pipeline with ~€16 bn opportunity (non-risk adjusted)
Asset pipeline with ~ € 16 bn opportunity (non-risk adjusted) Financial upside is becoming more tangible as pipeline broadens and assets advance Pipeline of product opportunities Existing portfolio with long-term revenue upside • >100 assets, of which 60% partnered Non-risk adjusted revenue, in € bn
Slide 22: Expecting meaningful pipeline advancements next 6-9 months
Expecting meaningful pipeline advancements next 6-9 months 13 partnered projects in pre-clinical & clinical stage, addressing markets in Onco, CNS, I&I Q1 2025 Today 2026 • Two assets in Ph III phase II in Q4 2025, expected to grow to up to four assets in Ph II Clinical 2026 • Number of assets Ph I
Slide 23: Pioneering Drug Discovery, Financials, Strategy & Outlook
1 Pioneering Drug Discovery 2 Financials 3 Strategy & Outlook PAGE 23
Slide 24: Condensed Income Statement Full-Year 2025
Condensed Income Statement Full-Year 2025 Strong growth in JEB while facing persistent softness in early discovery Three month ended Dec 31, Twelve month ended Dec 31, in € m1 2025 2024 Change 2025 2024 Change External Revenues 253.3 221.2 14.5% 788.4 797.0 -1.1% D&PD 137.1 164.4 -16.6% 528.9 611.4
Slide 25: Condensed Income Statement First Quarter 2026
Condensed Income Statement First Quarter 2026 Reported performance impacted by strong prior-year comparison and currency effects Three month ended Mar 31, in € m1 2026 2025 Change External Revenues 156.6 200.0 -43.4 D&PD 119.9 140.6 -20.7 JEB 36.8 59.4 -22.6 Gross margin -1.6 33.28 -34.85 D&PD 7.2 2
Slide 26: Q1 2026: Bridging Reported Results and Underlying Performance
Q1 2026: Bridging Reported Results and Underlying Performance Extraordinary prior-year effects and FX headwinds drive reported decline Q1 2025 Comparison €200,0 Adjusted for One-offs and FX Impacts €23,1 -6% €166,6 Group €10,2 €156,6 • Revenues decreased 6%, adjusted for Sandoz license sale and FX-i
Slide 27: Quarterly Liquidity Development
Quarterly Liquidity Development Solid balance sheet with net cash position at the end of the first quarter 2026 Net debt (net cash) 43 107 114 246 (40) (10) in € million Favorable changes in working 1 capital versus Q1 2025 supporting improved operating cash flow Disciplined capital expenditures 476
Slide 28: Pioneering Drug Discovery, Financials, Strategy & Outlook
1 Pioneering Drug Discovery 2 Financials 3 Strategy & Outlook PAGE 28
Slide 29: Horizon: Transforming Evotec for Sustainable Growth
Horizon: Transforming Evotec for Sustainable Growth Multi-stage transition from stabilization to intensified value creation 2026 2027 Reduce global footprint from Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 currently 14 sites to 10 Reduce workforce by approx. Operational 800 positions Workers Site closures* Council Exc
Slide 30: Full-year 2026 Revenue Outlook Driven By Segment Dynamics
Full-year 2026 Revenue Outlook Driven By Segment Dynamics Second half strengthening on segment growth and strategic contributions 371.2 Soft market impacting H1 2026 revenue • 2026 expansion of non-Sandoz H1 JEB customer value expected to Group Revenues more than offset reduced DoW €700-780 m revenu
Slide 31: Enabling Sustainable Growth by 2030
Enabling Sustainable Growth by 2030 2026-2030 medium-term framework aligned with Horizon transformation roadmap EBITDA margin 20% >20% Revenue CAGR >€1 bn (8-12% CAGR) PAGE 31
Slide 32: Roadmap to Sustainable Medium-Term EBITDA Expansion
Roadmap to Sustainable Medium-Term EBITDA Expansion Structural efficiencies and business growth driving margin improvement toward >20% by 2030 >20% • Customer base Horizon run rate cost savings • New products €75 million ~20% • Royalties • Customer base • New products • BMS collab. • Revenue growth
Slide 33: Key Messages
Key Messages Disciplined delivery, transformation in motion, and a clear path to sustainable value creation 1 Strong 2025 financial delivery at the high end of guidance, demonstrating disciplined execution, cost and CAPEX control 2 Clear and actionable pathway to sustainable, profitable growth throu
Slide 34: Appendix
Appendix PAGE 34
Slide 35: Experienced management team with long-term mission
Experienced management team with long-term mission The management team Experience Experience • 2017 – 2022 CEO of Mediq • 2023 –2025 CFO at BMI • 2005 – 2017 Various Group leadership positions at Linde • 2020–2022 Global Head Group, since 2007 member of Finance Operations at of the Group Executive N
Slide 36: Global view and deep experience for best governance
Global view and deep experience for best governance Independent and diverse Supervisory Board • Since 2014 Member of • Since 2019 Member of the • Since 2022 Member of Evotec’s Evotec’s Supervisory Board Supervisory Board Supervisory Board (2021 Chairperson) (2021 Vice Chairperson) • Since 2013, Diff
Slide 37: Shareholders supporting sustainable growth
Shareholders supporting sustainable growth Shareholder structure1 ~ 10% Triton GP HoldCo SARL ~ 7% Mubadala Investment Company ~ 83% Free float Number of shares: Listings: 52 week high/low: 177.9 m Frankfurt Stock Exchange (SDAX, TecDAX), Ticker: EVT € 8.57/€ 4.00 NASDAQ Global Select Market (ADS),
Slide 38: Dr. Sarah Fakih, EVP Head of Global Communications & Investor Relations
Dr. Sarah Fakih EVP Head of Global Communications & Investor Relations +49 (0) 151 70688784 (mobile) [email protected]